Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF ACCOUNTING OFFICER | July 15, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date July 15, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 29,062 |
Ending reported balance
After 2026-09-03 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-07-15 · Grant · Acquired 279 · Balance 27,697 F1: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e). Row 2 · 2026-09-01 · Exercise / conversion · Acquired 3,932 · Balance 31,629 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 2,558 · Balance 34,187 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,362 · Balance 36,549 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Exercise / conversion · Acquired 2,644 · Balance 39,193 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 6 · 2026-09-01 · Tax withholding · Disposed 5,531 · Balance 33,662 Row 7 · 2026-09-03 · Sale · Disposed 4,600 · Balance 29,062 F3: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,650 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Grant · Acquired 3,650 · Balance 3,650 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,931 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 2,644 · Balance 7,931 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 4,725 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,362 · Balance 4,725 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 2,557 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Exercise / conversion · Disposed 2,558 · Balance 2,557 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Exercise / conversion · Disposed 3,932 · Balance 0 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 14,600 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Grant · Acquired 14,600 · Balance 14,600 F5: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).
F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F3: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
F5: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F9: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 21,150 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · derivative · entry 10 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,150 Underlying: Class A Ordinary Share · 21,150 shares Expires 2035-08-31 F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 10,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · derivative · entry 9 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,575 Underlying: Class A Ordinary Share · 10,575 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 4,282 | $33.49 | $143,404.18 |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,612 Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 3,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,557 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:56 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023564 · form4-09032025_080915.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 17,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001415889-25-021177 · form4-08062025_040801.xml · derivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 17,000 shares Expires 2030-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 13, 2020. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 17,000 | $32.35 | $549,950.00 |
DisclosureSEC source: 0001415889-25-021177 · form4-08062025_040801.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,041 F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.01 and $32.895. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 17,000 | $15.52 | $263,840.00 |
DisclosureSEC source: 0001415889-25-021177 · form4-08062025_040801.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| July 15, 2025 Filed Aug 6, 2025 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Ordinary Share | 495 | $15.63 | $7,736.85 |
DisclosureSEC source: 0001415889-25-021177 · form4-08062025_040801.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,041 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2025 to July 15, 2025. The acquisition of these shares was exempt pursuant to Rule 16b-3(e). Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 15,211 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001415889-25-015782 · form4-06052025_080606.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 791 Underlying: Class A Ordinary Share · 15,211 shares Expires 2030-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 15,211 | $28.75 | $437,316.25 |
DisclosureSEC source: 0001415889-25-015782 · form4-06052025_080606.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.75 and $28.755. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:50 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 15,211 | $15.50 | $235,770.50 |
DisclosureSEC source: 0001415889-25-015782 · form4-06052025_080606.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 14,420 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-25-012532 · form4-05092025_080544.xml · derivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,040 Underlying: Class A Ordinary Share · 14,420 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 2,998 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001415889-25-012532 · form4-05092025_080544.xml · derivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,002 Underlying: Class A Ordinary Share · 2,998 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. F2 · derivative.expiration_date: The option is fully vested and exercisable. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 229 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001415889-25-012532 · form4-05092025_080544.xml · derivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 229 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F2 · derivative.exercise_date: The option is fully vested and exercisable. F2 · derivative.expiration_date: The option is fully vested and exercisable. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 17,647 | $26.69 | $470,998.43 |
DisclosureSEC source: 0001415889-25-012532 · form4-05092025_080544.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,546 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 14,420 | $11.97 | $172,607.40 |
DisclosureSEC source: 0001415889-25-012532 · form4-05092025_080544.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,193 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,998 | $15.50 | $46,469.00 |
DisclosureSEC source: 0001415889-25-012532 · form4-05092025_080544.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| May 07, 2025 Filed May 9, 2025 20:59 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 229 | $8.83 | $2,022.07 |
DisclosureSEC source: 0001415889-25-012532 · form4-05092025_080544.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 5,456 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011985 · form4-05052025_080516.xml · derivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,456 Underlying: Class A Ordinary Share · 5,456 shares Expires 2035-04-30 F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F6 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Option · Derivative | 5,285 | $0.00 Strike: $27.74 | $0.00 |
DisclosureSEC source: 0001415889-25-011985 · form4-05052025_080516.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,285 Underlying: Class A Ordinary Share · 5,285 shares Expires 2035-04-30 F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F5 · derivative.exercise_date: The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 3,433 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011985 · form4-05052025_080516.xml · derivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,433 Underlying: Class A Ordinary Share · 3,433 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F4 · derivative.exercise_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. F4 · derivative.expiration_date: The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 3,270 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011985 · form4-05052025_080516.xml · derivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,270 Underlying: Class A Ordinary Share · 3,270 shares Expires not disclosed F1 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F2 · shares: The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement. F3 · derivative.exercise_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. F3 · derivative.expiration_date: The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-010476 · form4-04092025_080447.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,932 Underlying: Class A Ordinary Share · 3,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,666 | $20.28 | $33,786.48 |
DisclosureSEC source: 0001415889-25-010476 · form4-04092025_080447.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,546 Read SEC document |
| April 07, 2025 Filed Apr 9, 2025 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 3,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010476 · form4-04092025_080447.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009991 · form4-04032025_080410.xml · derivative · entry 8 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,087 Underlying: Class A Ordinary Share · 2,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009991 · form4-04032025_080410.xml · derivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,115 Underlying: Class A Ordinary Share · 2,557 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 10,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009991 · form4-04032025_080410.xml · derivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,575 Underlying: Class A Ordinary Share · 10,575 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 21,150 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0001415889-25-009991 · form4-04032025_080410.xml · derivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,150 Underlying: Class A Ordinary Share · 21,150 shares Expires 2035-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,001 | $21.77 | $21,791.77 |
DisclosureSEC source: 0001415889-25-009991 · form4-04032025_080410.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,279 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,083 | $21.77 | $23,576.91 |
DisclosureSEC source: 0001415889-25-009991 · form4-04032025_080410.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,280 Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-009991 · form4-04032025_080410.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:52 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,557 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-009991 · form4-04032025_080410.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 774 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008618 · form4-03192025_090332.xml · derivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 328 | $22.61 | $7,416.08 |
DisclosureSEC source: 0001415889-25-008618 · form4-03192025_090332.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,443 Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-008618 · form4-03192025_090332.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,771 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 9,051 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-25-008117 · form4-03142025_080322.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,763 Underlying: Class A Ordinary Share · 9,051 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 9,051 | $22.45 | $203,194.95 |
DisclosureSEC source: 0001415889-25-008117 · form4-03142025_080322.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,528 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $22.45 and $22.465. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 9,051 | $11.10 | $100,466.10 |
DisclosureSEC source: 0001415889-25-008117 · form4-03142025_080322.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| January 15, 2025 Filed Mar 19, 2025 21:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Ordinary Share | 469 | $16.00 | $7,504.00 |
DisclosureSEC source: 0001415889-25-008618 · form4-03192025_090332.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,997 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2024 to January 15, 2025. The acquisition of such shares was exempt pursuant to Rule 16b-3(e). Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 9 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-24-027993 · form4-12022024_091211.xml · derivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,814 Underlying: Class A Ordinary Share · 9 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 9 | $22.45 | $202.05 |
DisclosureSEC source: 0001415889-24-027993 · form4-12022024_091211.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,528 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| November 29, 2024 Filed Dec 2, 2024 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 9 | $11.10 | $99.90 |
DisclosureSEC source: 0001415889-24-027993 · form4-12022024_091211.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 8,637 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-24-027993 · form4-12022024_091211.xml · derivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,823 Underlying: Class A Ordinary Share · 8,637 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 8,637 | $22.45 | $193,900.65 |
DisclosureSEC source: 0001415889-24-027993 · form4-12022024_091211.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,528 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $22.45 and $22.465. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| November 27, 2024 Filed Dec 2, 2024 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 8,637 | $11.10 | $95,870.70 |
DisclosureSEC source: 0001415889-24-027993 · form4-12022024_091211.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 175 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024885 · form4-10082024_081027.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175 Underlying: Class A Ordinary Share · 175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. F2 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 82 | $24.48 | $2,007.36 |
DisclosureSEC source: 0001415889-24-024885 · form4-10082024_081027.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,528 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.